Structure Therapeutics is trading 4.2% up at $48.97 in pre-market action, resuming its upward trend following a brief pullback on July 20.
- The stock's recent surge is fueled by strong Phase 2b data for its oral GLP-1 obesity candidate, aleniglipron, which demonstrated double-digit weight loss.
- Investors remain focused on the company's plans to advance the treatment into Phase 3 trials, with today's move appearing to be a continuation of that clinical optimism.